Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection

Immunotherapy
Pramod K GiriGopal K Khuller

Abstract

This study was designed to evaluate the immunotherapeutic potential of Mycobacterium tuberculosis Ag85AB emulsified with unmethylated CpG motif-containing oligonucleotide (CpG-ODN) and dimethyldioctadecylammonium bromide (DDA) adjuvants (Ag85AB-CpG-DDA) in conjunction with antituberculous drugs. Ag85 complex proteins of M. tuberculosis purified from total culture filtrate and purified proteins were emulsified with CpG-ODN and DDA adjuvants. Mice were infected with M. tuberculosis H37 Rv and left for 30 days to establish infection. These mice were named 'tuberculous mice'. Tuberculous mice were treated with Ag85AB-CpG-DDA alone or in conjunction with antituberculous drugs. Treatment of tuberculous mice with Ag85AB-CpG-DDA in conjunction with antituberculous drugs reduced significant bacilli burden in lung and spleen. Moreover, treatment of tuberculous mice with Ag85AB-CpG-DDA induced higher production of type-I cytokines, generated more CD44-positive T cells and suppresses secretion of IL-4 as compared with untreated animals. In conclusion, this study shows that Ag85AB-CpG-DDA formulation may act as a potential future therapeutic regimen in conjunction with antituberculous drugs.

References

Dec 1, 1993·The Journal of Experimental Medicine·J L FlynnB R Bloom
May 14, 1993·Science·A Lanzavecchia
Oct 31, 1996·Nature·A K AbbasA Sher
Jul 27, 1999·Nature·D B LowrieC L Silva
Jan 20, 2000·Infection and Immunity·L BrandtP Andersen
Jul 19, 2000·Current Opinion in Immunology·J L Flynn, J D Ernst
Sep 6, 2000·Nature Medicine·S H Kaufmann
May 31, 2001·Immunology·H L Collins, S H Kaufmann
Dec 19, 2001·Infection and Immunity·Nicole P JuffermansTom van der Poll
Mar 26, 2003·Infection and Immunity·Jennifer L TaylorIan M Orme
Aug 1, 1964·Canadian Journal of Biochemistry·D SUBRAHMANYAM
Sep 21, 2004·The Journal of Infectious Diseases·Anjana KalitaG K Khuller
Nov 17, 2004·Current Pharmaceutical Design·Haruaki Tomioka

❮ Previous
Next ❯

Citations

Feb 24, 2012·Journal of Biosciences·Natarajan PalaniappanSujatha Narayanan
Jun 28, 2011·Journal of Immune Based Therapies and Vaccines·Javaid A SheikhIndu Verma
Sep 18, 2012·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C D RochaA A M Coelho-Castelo
Oct 30, 2009·Expert Review of Vaccines·Indu Verma, Ajay Grover
Jun 21, 2011·Enfermedades infecciosas y microbiología clínica·Virgilio Bocanegra-GarcíaJosé Prisco Palma-Nicolás
Jul 1, 2020·Immunological Reviews·Virgil SchijnsEd C Lavelle
Oct 7, 2021·ACS Infectious Diseases·Mohammad AqdasJaved Naim Agrewala

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometery
ELISA
flow cytometry
FACS

Software Mentioned

CellQuest

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.